Please login to the form below

Not currently logged in
Email:
Password:

Almirall launches Solaraze in Spain

Pharma company says move strengthens its dermatology business strategy

Almirall has launched its actinic keratosis treatment Solaraze (diclofenac sodium and hyaluronic acid) in Spain.

Barcelona-based Almirall said the domestic launch of Solaraze consolidates its business strategy in dermatology, which along with respiratory R&D makes up the firm's key research focus.

Through a gel formulation applied twice a day for 90 days Solaraze stimulates the skin's defence system to destroy damaged cells and encourage healthy cells to replace them.

Actinic keratosis is a pre-cancerous lesion that an estimated one in six people will develop at some point in their lives.

Also known as solar keratosis, actinic keratosis appears as a small scaly or rough bump on the skin's surface. It takes years to develop and usually appears on the face, ears or scalp, the neck and back of hands and forearms and on the lips.

The lesions, which are most often caused by exposure to the sun, are not usually life-threatening if they are detected and treated in the early stages.

Solarze was developed by SkyePharma and first marketed by Shire Pharmaceuticals, until Almirall acquired the product, and seven others, in a $213m deal in 2007.

15th December 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics